This is interestingFor these older boys who have limited...

This is interesting





For these older boys who have limited therapeutic options, these data support the belief that CAP-1002 may become an important therapeutic option and possibly slow the progression of DMD," said McDonald.CAP-1002 consists of donor cardiosphere-derived cells (CDCs) given by intravenous infusion once every three months that is thought to modulate the immune system and regenerate skeletal and cardiac muscle cells.

The cells are not thought to engraft into muscle, but exert their effects by secreting various anti-inflammatory and regenerative factors.The planned phase 3 trial – HOPE-3 – is designed to include 65 to 75 patients enrolled across 20 sites in the US,

according to Capricor, which sees CAP-1002 as an add-on therapy to current treatments for DMD, including steroids and exon-skipping therapies like Sarepta's Exondys 51 (eteplirsen) and Vyondys 53 (golodirsen) as well as NPS Pharma's Viltepso (viltolarsen)

.CAP-1002 was formerly partnered by Johnson & Johnson in a 2014 deal as a potential treatment for myocardial infarction, but J&J returned rights to the drug after it failed a phase 2 trial.”